Soldevir V Tablet contains Sofosbuvir 400 mg and Velpatasvir 100 mg, a fixed-dose pan-genotypic antiviral combination designed for effective treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir acts as a nucleotide analogue NS5B polymerase inhibitor, while Velpatasvir inhibits the NS5A protein, together blocking viral replication at multiple stages of the HCV lifecycle.
Clinically, this combination is indicated for all major HCV genotypes (1–6), including patients with compensated cirrhosis and treatment-naïve or treatment-experienced cases. The dual mechanism results in high sustained virologic response (SVR) rates, making it a cornerstone therapy in modern hepatitis C management.
The tablet formulation ensures consistent bioavailability, precise dosing, and reliable antiviral efficacy, making it suitable for hepatology clinics, gastroenterology centers, hospitals, and specialty pharmacies. Oral once-daily administration supports excellent patient compliance during the treatment course.
Soldevir V Tablet helps in rapid viral clearance, prevention of liver disease progression, and reduction in long-term complications such as cirrhosis and hepatocellular carcinoma. Its proven safety and efficacy profile make it a trusted antiviral therapy for chronic hepatitis C when used under strict medical supervision.